구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Hydroxyurea (HU) |
Overview Company | Bionoxx Inc. |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Treatment-Refractory Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | , represents a significant advance in phytomedicine-based approaches to obesity treatment |
MoA Biomarker | biomarker in Parkinson's disease (PD), but its levels are influenced by dopamine replacement therapy (DRT), c |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Disulfide rebridging platforms for site-specific ADC conjugation.. Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted therapeutics, combining the exquisite specificity of monoclonal antibodies with the potency of small-molecule cytotoxic payloads. While numerous strategies exist to generate ADCs, site-specific conjugation methods have gained prominence due to their … |
Toxicology CRS | Reported |
Clinical Safety signal | Disulfide rebridging platforms for site-specific ADC conjugation.. Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted therapeutics, combining the exquisite specificity of monoclonal antibodies with the potency of small-molecule cytotoxic payloads. While numerous strategies exist to generate ADCs, site-specific conjugation methods have gained prominence due to their … |
Clinical Selected reported efficacy | ORR 18% |
Clinical Reported ORR | 18% |
Clinical Result source | ClinicalTrials.gov NCT01657682 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01657682 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Hydroxyurea (HU) |
Overview Company | Bionoxx Inc. |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Treatment-Refractory Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | , represents a significant advance in phytomedicine-based approaches to obesity treatment |
MoA Biomarker | biomarker in Parkinson's disease (PD), but its levels are influenced by dopamine replacement therapy (DRT), c |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Disulfide rebridging platforms for site-specific ADC conjugation.. Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted therapeutics, combining the exquisite specificity of monoclonal antibodies with the potency of small-molecule cytotoxic payloads. While numerous strategies exist to generate ADCs, site-specific conjugation methods have gained prominence due to their … |
Toxicology CRS | Reported |
Clinical Safety signal | Disulfide rebridging platforms for site-specific ADC conjugation.. Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted therapeutics, combining the exquisite specificity of monoclonal antibodies with the potency of small-molecule cytotoxic payloads. While numerous strategies exist to generate ADCs, site-specific conjugation methods have gained prominence due to their … |
Clinical Selected reported efficacy | ORR 18% |
Clinical Reported ORR | 18% |
Clinical Result source | ClinicalTrials.gov NCT01657682 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01657682 |
추천 비교
추천 비교